CLINICAL_TRIALS
trial_result
· 2019-03-01
Clinical Trial Update: Afatinib in NSCLC With HER2 Mutation [Phase 2]
Summary
Phase 2 trial update of afatinib in non-small cell lung cancer with HER2 mutation has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ETOP IBCSG Partners Foundation | Conditions: NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2019-03-01